Krystal Biotech, Inc.
KRYS
$168.57
$3.872.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 116.26% | 879.91% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.26% | 879.91% | -- | -- | -- |
| Cost of Revenue | 72.38% | 2,897.31% | -- | -- | -- |
| Gross Profit | 119.47% | 825.92% | -- | -- | -- |
| SG&A Expenses | 26.34% | 21.17% | 6.65% | 8.42% | 1.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.57% | 41.56% | 29.36% | 8.56% | 11.12% |
| Operating Income | 1,218.64% | 234.39% | 155.37% | 116.01% | 108.94% |
| Income Before Tax | 356.13% | -63.13% | 148.31% | 102.06% | 133.25% |
| Income Tax Expenses | 59.34% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 423.23% | -66.34% | 146.88% | 102.06% | 127.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 423.23% | -66.34% | 146.88% | 102.06% | 127.12% |
| EBIT | 1,218.64% | 234.39% | 155.37% | 116.01% | 108.94% |
| EBITDA | 934.35% | 239.70% | 160.68% | 118.10% | 111.84% |
| EPS Basic | 412.51% | -67.13% | 143.70% | 101.87% | 124.73% |
| Normalized Basic EPS | 346.77% | 314.40% | 180.12% | 137.22% | 130.01% |
| EPS Diluted | 409.41% | -67.38% | 142.40% | 101.70% | 123.94% |
| Normalized Diluted EPS | 339.94% | 312.12% | 177.32% | 135.95% | 129.32% |
| Average Basic Shares Outstanding | 2.08% | 2.40% | 7.28% | 10.05% | 9.69% |
| Average Diluted Shares Outstanding | 3.70% | 3.50% | 11.18% | 13.92% | 12.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |